Current progress towards the development of tyrosine kinase inhibitors as anticancer agents

Bibliography

• HANKS SK, HUNTER T: Protein kinases 6 - the eukaryotic protein kinase superfamilykinase (catalytic) domain structure and classification. FASEB J. (1995) 9(8):576–596.
   PubMed Web of Science ®Google Scholar
• Cancer and cancer-related treatments. MedAdNews (1997) 16(5):70–74. ••
   Google Scholar
• KHAZAIE K, SCHIRRMACHER V, LICHTNER RB: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev. (1993) 12(3-4):255–274.
   PubMed Web of Science ®Google Scholar
• DAVIES DE, CHAMBERLIN SG: Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem. Pharmacol. (1996) 51 (9):1101–1110.
   PubMed Web of Science ®Google Scholar
• BARTLETT JMS, et al.: The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer (1996) 73(3) :301–306.
   PubMed Web of Science ®Google Scholar
• COFFEY RJ, et al.: Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Natl. Acad. Sci. USA (1997) 94(2) :657–662.
   PubMed Web of Science ®Google Scholar
• HAGMANN W, BORGERS S: Requirement for epidermal growth factor receptor tyrosine kinase and for 12-lipoxygenase activity in the expression of 12-lipoxygenase in human epidermoid carcinoma cells. Biochem. Pharmacol. (1997) 53(7)937–942.
   PubMed Web of Science ®Google Scholar
• BUNONE G, et al.: Activation of the unliganded oestrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. (1996) 15(9) :2174–2183.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO H, et al.: PDGF receptor-to-nucleus signalling of p91 (STAT1 alpha) transcription factor in rat smooth muscle cells. Exp. Cell. Res. (1996) 222(1):125–130.
   Google Scholar
• CAMORATTO AM, et al.: CEP-751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. Intern. J. Cancer (1997) 72(4) :673–679.
   PubMed Web of Science ®Google Scholar
• EDERY P, et al.: RET in human development and oncogenesis. Bioessays (1997) 19(5) :389–395.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO K, NAKAMURA T: Emerging multipotent aspects of hepatocyte growth factor. J. Biochem. Tokyo (1996) 119 (4) :591–600.
   PubMed Web of Science ®Google Scholar
• GISHIZKY ML: Molecular mechanisms of Bcr-Abl-induced oncogenesis. Cytokines Mol. Ther. (1996) 2(4):251–261.
   PubMedGoogle Scholar
• BOLEN JB, BRUGGE JS: Leukocyte protein tyrosine kinases: potential targets for drug discovery. Ann. Rev. Immunol. (1997) 15:371–404.
   PubMed Web of Science ®Google Scholar
• LEVITZKI A: SRC as a target for anti-cancer drugs. AntiCancer Drug Des. (1996) 11(3):175–182.
   PubMedGoogle Scholar
• MEYDAN N, et al.: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature(1996) 379(6566):645–648.
   PubMed Web of Science ®Google Scholar
• SHAWVER LK, et al.: Receptor tyrosine kinases as targets for inhibition of angiogenesis.Drug Disc. Today (1997) 2(2):50–63.
   Web of Science ®Google Scholar
• FOLKMAN J: What is the evidence that tumors are angiogenesis dependent J. Natl. CancerInst. (1989) 82(1):4–6.
   Web of Science ®Google Scholar
• PARANGI S, et al.: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA (1996) 93:2002–2007.
   PubMed Web of Science ®Google Scholar
• TRAXLER PM: Protein tyrosine kinase inhibitors in cancer treatment. Exp. Opin. Ther. Patents (1997) 7(6):571–588.
   Web of Science ®Google Scholar
• BRIDGES AJ: The epidermal growth factor receptor family of tyrosine kinases and cancer: can an atypical exemplar be a sound therapeutic target Curr. Med. Chem. (1996) 3 (1):167–196.
   Google Scholar
• BUCHDUNGER E, et al.: 4,5-Dianilinophthalimide - a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. USA (1994) 91 (6):2334–2338.
   PubMed Web of Science ®Google Scholar
• MATTAR T, et al.: Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. (1993) 334 (2) :161–164.
   PubMed Web of Science ®Google Scholar
• XU XL, et al.: Two activities of the immunosuppressive metabolite of leflunomide, All 1726 - inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem. Pharmacol. (1996) 52(4)527–534.
   Google Scholar
• CHERWINSKI HM, et al.: The immunosuppresant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. (1995) 275:1043–1049.
   PubMed Web of Science ®Google Scholar
• ZIMMERMANN J, et al.: Phenylamino-pyrimidine (PAP)-derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett (1996) 6(11):1221–1226.
   Web of Science ®Google Scholar
• HAMBY JM, et al.: Structure-activity relationships for a novel series of pyrido [2,3-d] pyrimidine tyrosine kinase inhibitors. J. Med. Chem. (1997) 40 (15):2296–2303.
   PubMed Web of Science ®Google Scholar
• HANKE JH, et al.: Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor - study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. (1996) 271 (2):695–701.
   PubMed Web of Science ®Google Scholar
• BUCHDUNGER E, et al.: Inhibition of the abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. (1996) 56(1)100–104.
   Google Scholar
• MOHAMMADI M, et al.: Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science (1997) 276(5314)955–960.
   PubMed Web of Science ®Google Scholar